Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Herbert Patterson

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Circulation. Heart Failure|October 26, 2018
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United StatesAdam D DeVore, C Larry Hill, Laine Thomas, et al.
Journal of Cardiac Failure|August 24, 2021
Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection FractionMuthiah Vaduganathan, Gregg C Fonarow, Stephen J Greene, et al.
Circulation. Heart Failure|October 22, 2021
Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure RegistryMuhammad Shahzeb Khan, Stephen J Greene, Anne S Hellkamp, et al.
American Heart Journal|June 20, 2017
Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registryAdam D DeVore, Laine Thomas, Nancy M Albert, et al.
Pharmacogenetics and Genomics|May 15, 2007
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failureMaximilian T Lobmeyer, Yan Gong, Steven G Terra, et al.
Circulation. Cardiovascular Quality and Outcomes|July 24, 2024
Association of Medication Adherence and Health Status in Heart Failure With Reduced Ejection Fraction: Insights From the CHAMP-HF RegistryRayan S El-Zein, Moghniuddin Mohammed, Daniel D Nguyen, et al.
Clinical and Translational Science|September 7, 2017
Precision Dosing: Public Health Need, Proposed Framework, and Anticipated ImpactDaniel Gonzalez, Gauri G Rao, Stacy C Bailey, et al.
Circulation. Cardiovascular Quality and Outcomes|April 9, 2018
Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) RegistryYevgeniy Khariton, Adrian F Hernandez, Gregg C Fonarow, et al.
JACC. Heart Failure|June 2, 2018
Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart FailureYevgeniy Khariton, Michael E Nassif, Laine Thomas, et al.
ESC Heart Failure|May 1, 2021
Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fractionMerrill Thomas, Yevgeniy Khariton, Gregg C Fonarow, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Circulation. Heart Failure|October 26, 2018
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United StatesAdam D DeVore, C Larry Hill, Laine Thomas, et al.
Journal of Cardiac Failure|August 24, 2021
Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection FractionMuthiah Vaduganathan, Gregg C Fonarow, Stephen J Greene, et al.
Circulation. Heart Failure|October 22, 2021
Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure RegistryMuhammad Shahzeb Khan, Stephen J Greene, Anne S Hellkamp, et al.
American Heart Journal|June 20, 2017
Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registryAdam D DeVore, Laine Thomas, Nancy M Albert, et al.
Pharmacogenetics and Genomics|May 15, 2007
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failureMaximilian T Lobmeyer, Yan Gong, Steven G Terra, et al.
Circulation. Cardiovascular Quality and Outcomes|July 24, 2024
Association of Medication Adherence and Health Status in Heart Failure With Reduced Ejection Fraction: Insights From the CHAMP-HF RegistryRayan S El-Zein, Moghniuddin Mohammed, Daniel D Nguyen, et al.
Clinical and Translational Science|September 7, 2017
Precision Dosing: Public Health Need, Proposed Framework, and Anticipated ImpactDaniel Gonzalez, Gauri G Rao, Stacy C Bailey, et al.
Circulation. Cardiovascular Quality and Outcomes|April 9, 2018
Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) RegistryYevgeniy Khariton, Adrian F Hernandez, Gregg C Fonarow, et al.
JACC. Heart Failure|June 2, 2018
Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart FailureYevgeniy Khariton, Michael E Nassif, Laine Thomas, et al.
ESC Heart Failure|May 1, 2021
Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fractionMerrill Thomas, Yevgeniy Khariton, Gregg C Fonarow, et al.
Pageof 7